COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection

COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection

In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared a global pandemic by the World Health Organization (WHO). The clinical course of the disease is unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to acute respiratory dist...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Katarzyna Kotfis, Kacper Lechowicz, Sylwester Drożdżal, Paulina Niedźwiedzka-Rystwej, Tomasz K. Wojdacz, Ewelina Grywalska, Jowita Biernawska, Magda Wiśniewska, Miłosz Parczewski
Formatua: Artikulua
Hizkuntza:English
Argitaratua: MDPI AG 2021-01-01
Saila:Pharmaceuticals
Gaiak:
COVID-19
SARS-CoV-2
coronavirus
pandemic
spironolactone
potassium canrenoate
Sarrera elektronikoa:https://www.mdpi.com/1424-8247/14/1/71

Internet

https://www.mdpi.com/1424-8247/14/1/71

Antzeko izenburuak